High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. (Q38391222)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809392%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

0 references

1 reference

title

High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809392%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809392%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Christophe Bauters

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809392%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

G Schurtz

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809392%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

M Hamon

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809392%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

1 reference

21 April 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809392%20AND%20SRC:MED&resulttype=core&format=json

Journal of Thrombosis and Haemostasis

3 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809392%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809392%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809392%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

931-942

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809392%20AND%20SRC:MED&resulttype=core&format=json

Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data

3 March 2020

cites work

1 reference

Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study

21 January 2018

1 reference

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 January 2018

1 reference

Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation

21 January 2018

1 reference

A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial

21 January 2018

1 reference

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

21 January 2018

1 reference

Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy

21 January 2018

1 reference

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE

21 January 2018

1 reference

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

21 January 2018

1 reference

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction

21 January 2018

1 reference

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes

21 January 2018

1 reference

Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparison.

21 January 2018

1 reference

Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study.

21 January 2018

1 reference

Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2).

21 January 2018

1 reference

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study

21 January 2018

1 reference

Poor agreement between light transmission aggregometry, Verify Now P2Y₁₂ and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials.

21 January 2018

1 reference

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

21 January 2018

1 reference

Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.

21 January 2018

1 reference

A(2A) adenosine receptors in human peripheral blood cells

21 January 2018

1 reference

Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies.

21 January 2018

1 reference

Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).

21 January 2018

1 reference

Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (IS

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JTH.12907

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809392%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference